Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology

BACKGROUND: Incremental cost-effectiveness ratios (ICERs) are used to assess the value for money of new drugs. Many believe that ICERs for drugs that treat rare diseases are much higher than those of common drugs. Our objective was to compare the proportion of ICERs that are cost effective for rare...

Descripción completa

Detalles Bibliográficos
Autores principales: Jayasundara, Kavisha, Krahn, Murray, Mamdani, Muhammad, Hoch, Jeffrey S., Grootendorst, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5691840/
https://www.ncbi.nlm.nih.gov/pubmed/29441496
http://dx.doi.org/10.1007/s41669-017-0022-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5691840/
https://www.ncbi.nlm.nih.gov/pubmed/29441496
http://dx.doi.org/10.1007/s41669-017-0022-7

Ejemplares similares